Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.

Slides:



Advertisements
Similar presentations
Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.
Advertisements

Gynecologic Oncology Group Gynecologic Oncology Group Uterine Corpus Trials: GCIG David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation.
Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.
Clinical Implementation of Genomic Cancer Medicine
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.
Michael Birrer, PI, Director, Gynecologic Medical Oncology, MGH Lari Wenzel, Co-PI, Prof. of Medicine, University of California, Irvine
Ovarian Cancer Gloria S. Huang, M.D. Assistant Professor Department of Obstetrics & Gynecology and Women ’ s Health Division of Gynecologic Oncology Albert.
Can We Define Tumors That Will Respond to PARP Inhibitors? A Phase II Correlative Study of Olaparib in Advanced Serous Ovarian Cancer and Triple-Negative.
Julie R. Gralow, M.D. Director, Breast Medical Oncology, Seattle Cancer Care Alliance Professor, Medical Oncology, University of Washington School of Medicine.
What are clinical trials? Phases of Clinical Trials Clinical trials of new medicines are done in phases: Phase I Phase II Phase III.
Evaluating cell lines as tumor models by comparison of genomic profiles Domcke, S. et al. Nat. Commun 4:2126.
Northern England Strategic Clinical Network Conference Thyroid Sub-group Update Dr Sath Nag Consultant Endocrinologist Vice Chair, Thyroid NSSG South Tees.
Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.
Precision Medicine: From stratified therapies to personalized therapies Fabrice ANDRE Institut Gustave Roussy Villejuif, France.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture By: Reem Sallam, MD, MSc, PhD.
Evidence Based Decision Making In Gynecologic Cancer Paolo Zola Turin, ITALY Adriana Bermudez Buenos Aires, ARGENTINA.
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology.
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
Molecular Biomarkers in Radiotherapy of Cervical Cancer A collaboration project between Department of Gynecologic Oncology and Department of Radiation.
Margaret Tempero, M.D. Professor of Medicine University of California, San Francisco Debate: This house believes that FOLFIRINOX is the best treatment.
Fallopian Tube and Ovarian Malignancy Schwartz's Principles of Surgery Chapter 41. Gynecology.
4% of all female cancers 25% of all gynecologic cancers life time risk: 1/70 ¾ advanced stage most lethal Epithelial Ovarian Cancer:
Are there benefits from chemotherapy to early endometrial cancer
10 Minutes Talk 吳 華 席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Sep 08, 2008.
Lymphadenectomy in Epithelial Ovarian Cancer
GI-NEUROENDOCRINE TUMORS THERAPEUTIC APROACHES Chemotherapy: older and recent schemes Ilias Athanasiadis, MD Medical Oncologist Director of the Oncology.
1 Jack London, PhD Research Professor, Cancer Biology Thomas Jefferson University Informatics Shared Resource Director Sidney Kimmel Cancer Center at Jefferson.
Dubsky P et al. Proc SABCS 2012;Abstract S4-3.
Huidi Liu, M.D. & Ph.D Genomics Research Centre Harbin Medical University, China Reduced expression of SOX7 in ovarian cancer: a novel.
IGF-1R: A key linker between chemoresistance and cancer stem cells in epithelial ovarian cancer cells Ram Kumar Singh, Ankit Jinager, Ajit Dhadwe, Abhijit.
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
Gene Expression Signatures for Prognosis in NSCLC, Coupled with Signatures of Oncogenic Pathway Deregulation, Provide a Novel Approach for Selection of.
GOG0172: The Dings The recommended regimen is not feasible –Substitution of carboplatin for cisplatin –Reduce cisplatin from 100 mg/m 2 to 75 mg/m 2 –Change.
Introduction Ignace Vergote, MD Department of Obstetrics and Gynaecology Gynaecologic Oncology Catholic University of Leuven Leuven, Belgium.
Adam Heathfield, PhD Senior Director, Worldwide Policy, Pfizer Inc. September 25, 2013 Personalised Medicine – an industry perspective.
Using Predictive Classifiers in the Design of Phase III Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.
Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.
Rationale for Developing New Drugs 25% of children with cancer will not survive 5 years25% of children with cancer will not survive 5 years The acute toxicity.
Integrating Pharmacogenomic Questions Into GCIG Ovarian Cancer Clinical Trials Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research.
Jin MENG Shen FU (DPD 08) Biology 2 - Head/Neck and CNS Tumors
Pan-cancer analysis of prognostic genes Jordan Anaya Omnes Res, In this study I have used publicly available clinical and.
Scott Kopetz, MD, PhD Department of Gastrointestinal Medical Oncology
Progress in Cancer Therapy Following Developments in Biopharma
Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.
ENDOMETRIAL CARCINOMA UPDATES Dr Marco Matos Gold Coast Cancer Care, Gold Coast University Hospital and Pacific Private Oncology Group.
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
1 Trends in drug development programs in the era of Personalized Medicine Gunnar Saeter, M.D., Ph.D. Head, Institute for Cancer Research Oslo University.
XXV^ Riunione Nazionale MITO Innovation in gynecologic cancer: optimal therapy, quality of life, precision medicine. Naples, June Targeting.
MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
Chips? SNPs? or PCR? What do we really want and what do we need? Heinz-Josef Lenz, MD Professor of Medicine Co-Director, Colorectal Center Co-Director,
What should patients with BRAF mutant melanoma receive as front line therapy? Antoni Ribas, M.D. Professor of Medicine Professor of Surgery Professor of.
Department of Pathology UC Davis School of Medicine Jeff Gregg, M.D. The Development of an Informatics Platform for the Characterization of Clinical Samples.
Drug Development at CINJ Evolving challenges. Phase 1 Studies at CINJ Early drug trials– Fits easily in scope for single or limited number of institutions.
종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.
R2 김재민 / Prof. 정재헌 Journal conference 1.
Clinical and Research Updates in Gynecologic Oncology
Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.
Abramson Cancer Center Director’s Leadership Council March 13, 2017
Uterine serous carcinoma is more aggressive than high-grade serous ovarian carcinoma: a retrospective study H. Nagano1, Y. Tachibana1, M. Kawakami1, M.
Figure #1 Overall survival Figure #2 Disease free survival
New Views into the Prostate Cancer Genome
Figure 2 Multiscale modelling in oncology
Treatment Overview: The Multidisciplinary Team
Class Prediction Based on Gene Expression Data Issues in the Design and Analysis of Microarray Experiments Michael D. Radmacher, Ph.D. Biometric Research.
Volume 147, Issue 2, Pages (November 2017)
Molecular prognostication of liver cancer: End of the beginning
Overall Survival and Progression-free Survival
Receipt of Adjuvant Endometrial Cancer Treatment According to Race NRG Oncology/Gynecologic Oncology Group (GOG) 210 Study Ashley Felix, PhD, MPH Assistant.
Presentation transcript:

Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer

Ovarian Cancer Historic Perspective All serous tumors thought to arise from surface epithelium/inclusion cysts. All serous tumors thought to arise from surface epithelium/inclusion cysts. 75% patients present with advanced stage disease. 75% patients present with advanced stage disease. 80% respond to chemotherapy. 80% respond to chemotherapy. Vast majority of patients relapse and eventually develop drug resistant disease. Vast majority of patients relapse and eventually develop drug resistant disease. Minimal increase in overall survival over last 30 years. Minimal increase in overall survival over last 30 years. All patients treated with surgery and chemotherapy. All patients treated with surgery and chemotherapy.

New Development in Biology Origins

Integrating the models of serous carcinogenesis – a binary model Levanon, Crum, and Drapkin, JCO, 2008

How does it affect screening? Is the target lesion a 1mm lesion in the fallopian tube? Is the target lesion a 1mm lesion in the fallopian tube? How rapidly do these progress? How rapidly do these progress? What about tumors arising from the surface of the ovary? What about tumors arising from the surface of the ovary?

How does it affect treatment? Two types of Serous Tumors? Surface Epithelium versus Fallopian tube Are they biologically the same?

Is Ovarian Cancer a Homogenous Disease? Histology

OVARIAN AND ENDOMETRIAL CANCER SUBTYPES SEROUS ENDOMETRIOID CLEAR CELL OVARY ENDOMETRIUM

OVARIAN & ENDOMETRIAL CANCER OVARIAN ENDO & SEROUS ENDOMETRIAL ENDO & SEROUS OVARIAN CLEAR CELL ENDOMETRIAL CLEAR CELL Zorn et. al. Clinical Cancer Research 2005

CLEAR CELL CANCER OVARIAN ENDOMETRIAL RENAL Zorn et. al. Clinical Cancer Research 2005

Clinical Impact of Genomic Characterization of Clear Cell Cancers Remove clear cell tumors from ovarian cancer phase III trials. Remove clear cell tumors from ovarian cancer phase III trials. Create clear cell specific phase II trials. Create clear cell specific phase II trials. Utilize understanding of molecular pathways of clear cell cancers from other organs to better treat ovarian cancer. Utilize understanding of molecular pathways of clear cell cancers from other organs to better treat ovarian cancer.

Expression Profiling of Clear Cell Tumors of the Ovary 15 clear cell cancers of the ovary 15 clear cell cancers of the ovary Whole genome profiling Whole genome profiling Supervised clustering Supervised clustering Pathway identification Pathway identification

Cell Cycle Progression Glycolysis HIF1alpha degradation Angiogenesis Clear Cell Ovarian Cancer HIF1 alpha Pathway Cell Migration

Is ovarian cancer a homogenous disease? Grade

Unsupervised Hierarchical Clustering of Serous Ovarian Cancers

Ovarian Cancer Normal Cells Papillary Serous Ovarian Tumors LMP/Low Grade High Grade P53- P53+ B-raf, ras Bonome et al Cancer Research 2005

Low Grade Phase II Trials GOG 239 AZ MEK Inhibitor

What About Papillary Serous Ovarian Cancer? 90% of ovarian cancers are papillary serous tumors. All tumors high grade tumors treated with surgery and chemotherapy. Activated pathways remain unknown.

Copyright ©2008 American Association for Cancer Research Tothill, R. W. et al. Clin Cancer Res 2008;14: Figure 5">

Optimally Debulked Suboptimally Debulked Gene signatures predicts survival only for suboptimally debulked tumors

Co-regulated Signaling Events In Sub-optimal Patient Subgroups

TCGA 200 high grade serous ovarian cancers 200 high grade serous ovarian cancers 6000 genes sequenced 6000 genes sequenced Expression profiling Expression profiling Copy number differences Copy number differences Methylation status Methylation status

Future Directions Histo/grade specific trials and regimens. Histo/grade specific trials and regimens. Identification of sub-groups of patients based upon genomic patterns and activated pathways. Identification of sub-groups of patients based upon genomic patterns and activated pathways.

Future Challenges Validation of prognostic and predictive biomarkers. Validation of prognostic and predictive biomarkers. Larger numbers of carefully annotated specimens Larger numbers of carefully annotated specimens FFPE technologies FFPE technologies Identification and validation of small molecule inhibitors targeting pathways Identification and validation of small molecule inhibitors targeting pathways Integrated biomarkers will be mandated. Integrated biomarkers will be mandated. Molecular basis for resistance Molecular basis for resistance Recurrent tumor biopsies should be a requirement. Recurrent tumor biopsies should be a requirement.

Michael J. Birrer M.D. Ph.D. Professor of Medicine Harvard Medical School Director Gynecologic Medical Oncology Massachusetts General Hospital